

DAFTAR PUSTAKA

1. Fawzy A, Pool LJ. Benign prostate hyperthrophy and the role of alpha adrenergic blockade. Release date : Sept 30, 2003; terdapat di <http://www.medscape.com>.
2. Mc Connel JD, Roehrborn CG. Etiology, pathophysiology, and natural history of benign prostatic hyperplasia. In : Walsh PC, Retik AB, Vaughan ED Jr, Wein A eds. Campbell's urology 8th ed. WB Saunders. Philadelphia. 2002 : 1297-330.
3. Yuwana R. Permasalahan Bedah Urologi pada Manula. Semarang : UPG Ilmu Bedah FK Undip.
4. Rachmat BP, Soetojo. Perbedaan kadar PSA dan TGF β -1 terhadap pemberian kombinasi 5α reduktase inhibitor (dutasteride) dan anti estrogen (tamoxifen) pada penderita BPH-LUTS. Fakultas Kedokteran Unair Surabaya; 2006.
5. Tohir G A., Prostatektomi Transvesikal : Faktor yang berperan terhadap perdarahan. 1992 Bagian bedah FK Undip / RSDK Semarang.
6. Haryanto AS. Perbandingan perdarahan pada operasi TVP antara teknik penjahitan leher buli konvensional dan dobel semi sirkuler. Karya Akhir Penelitian. Bagian Bedah FK Undip/RSDK. Semarang.
7. Robert G Hahn, Fagerstrom T, Tammela TL, Van Vierssen TO, Beisland HO, Duggan A et al. Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride. BJU Int 2007 vol 99 : 587-94
8. Shanmugasundaram R, Singh JC, Kekre NS. Does dutasteride reduce perioperative blood loss and postoperative complications after transurethral resection of the prostate?. 2007. Uroscan Vol 23(3) : 334-35
9. Walsh PC, Retik AB. Transurethral surgery. In : Campbell's urology 7th ed. WB saunders. Philadelphia, 1998 : 1511-28.

10. Foley CL, Bott SR, Kirby RS. An update on the 5 alpha reductase inhibitor. *Timely Top Med Urol* 2003 vol 4, Jun 2003
11. Chapple CR. Pharmacological therapy of benign prostatic/lower urinary tract symptoms:an overview for the practicing clinician. *BJU Int* 2004 vol 94 : 738-44.
12. Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, Roehrborn C et al. Dihydrotestosterone and the prostate: The scientific rationale for 5 α reductase inhibitors in the treatment of benign prostatic hyperplasia. *The Journal of Urol.* Vol 172, Oct 2004 : 1399-403.
13. Ku JH, Shin JK, Cho MC, Myung JK, Moon KC., Paick JS. Effect of dutasteride on the expression of hypoxia-inducible factor-1alpha, vascular endothelial growth factor and microvessel density in rat and human prostate tissue. *Scand J Urol Nephrol.* 2009;43(6): 445 – 53.
14. Lekas AG, Lazaris AC, Chrisofos M, Papatsoris AG, Lappas D, Patsouris E, et al. Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia.*Urology.* 2006 Aug;68(2):436-41.
15. Kravchick S, Peled R, Cytron S. Effect of short term dutasteride therapy on prostate vascularity in patients with BPH : A pilot study. *EAU 2007*, March 2007.
16. Lekas E, Bergh A, Damber E. Effects of finasteride and bicalutamide on prostatic blood flow in the rat, *BJU Inter*, 2000, 85 : 962-65.
17. Nickel JC. Comparisson of clinical trial with finasteride and dutasteride. *Rev Urol.* 2004;6(suppl 9):S31-S39
18. Sutton MT, Yingling M, Vyas A, Atiemo H, Borkowski A, Jacobs SC et al.. Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells.
19. Canda AE, Mungan MU, Yilmaz O, Yorukoglu K, Tuzel E, Kirkali Z. Effects of finasteride on the vascular surface density,number of microvessels and vascular

- endothelial growth factor expression of the rat prostate. *International Urology and Nephrology*. Vol 38(2), Juli 2006 : 275-80.
20. Crea G, Sanfilippo G. Pre-surgical finasteride therapy in patients treated endoscopically for BPH, *Urologia Internationalis*, 2005;74:51-3.
 21. Izawa JI, Dinney CPN. The role of angiogenesis in prostate and other urologic cancers : a review. *CMAJ* vol 164(5), March 2001
 22. Cao Y, Cao R. Angiogenesis inhibited by drinking tea. e-mail : yihai.cao@mtc.ki.se
 23. Fassina G, Vene R, Morini M, Minghelli S, Benelli R, Noonan DM et al. Mechanism of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin 3 gallate. *Clinical Cancer Research*, July 15, 2004 vol 10, p:4865-73.
 24. Thomas R., Kim MH., Epigallocatechin gallate inhibits HIF-1 α degradation in prostate cancer cells. *Biochem Biophys Res Commun*. 2005 Aug 26;334(2):543-8
 25. Nguyen LL, D'Amore PA. Cellular interactions in vascular growth and development. *Int Rev Cytol* 2001;204:1-48.
 26. Jain RK. Normalizing tumor vasculature with anti angiogenic therapy: a new paradigm for combination therapy. *Nat Med* 2001;7:987-9.
 27. Gerwins P, Skoldenberg E, Claesson Welsh L. Function of fibroblast growth factors and vascular endothelial growth factors and receptors in angiogenesis. *Crit Rev oncol Hematol* 2000;34:185-94.
 28. Beck L, D'Amore. Vascular development : cellular and molecular regulation. *FASEB J* 1997;11 : 365-73.
 29. Presti JC. Neoplasm of the prostatic gland. In : Tanagho EA, Mc Aninch JW eds. *Smith's general urology* 15th ed. Lange Medical Books/Mc Graw Hill. New York. 2000 : 399-417.
 30. Healey JE, Hodge J. *Surgical anatomy* 2nd ed. B.C. Decker Inc. Philadelphia. 1990 : 216.

31. Risau W. Mechanism of angiogenesis. *Nature* 1997;386:671-4
32. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Stanley J, Wiegand et al. Vascular-specific growth factors and blood vessel formation. *Nature* 2000;407:242-8.
33. Carmeliat P Mechanism of angiogenesis and arteriogenesis. *Nat Med* 2000;6:389-5.
34. Haris AL. Angiogenesis for cancer therapy. *Lancet* 1997, 349, 13-5.
35. Philp EA, Stephenson TJ, Reed MWR. Prognostic significance of angiogenesis in transitional cell carcinoma of the human urinary bladder, *Br J Urol*, 1995, 154 : 1779-82.
36. Delahunt B, Bethwaite PB, Thornton A. Prognostic significance of microscopic vascularity for clear cell renal cell carcinoma, *Br J Urol*, 1997, 80 : 401-4.
37. Walsh K, Sherwood RA, Dew TK, Mulvin D. Angiogenic peptides in prostatic disease ,*BJU Inter*, 1999, 84 : 1081-3.
38. Hadipriyono S, Purnomo BB. Pengaruh kateterisasi terhadap angiogenesis jaringan prostat pada pasien BPH di RSUD Dr. Saiful Anwar Malang, Lab/SMF Bedah Fak Kedokteran Universitas Brawijaya Malang, 2002
39. Pareek G, Shevchuk M, Armenakas NA, Vasjovic L, Hochberg DA, Bassilote JB, et al. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density. A possible mechanism for decreased prostatic bleeding in treated patients, *J Urol*, 2003, 169 : 20-3
40. Izawa JJ, Dinney CPN. The role of angiogenesis in prostate and other urologic cancers : a review, *CMAJ*, 2001, 164(5) : 662-70
41. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptor. *Nat Med* 2003;9:669-76.
42. Berger G, Benjamin LE. Tumorigenesis and the angiogenic switch. *Nat Rev Cancer* 2003; 3 : 401-10.
43. Jain RK. Molecular regulation of vessel maturation. *Nat Med* 2003; 9 : 685-93

44. Chang YS, di Tomaso E, Mc Donald DM, Jones R, Jain RK, Munn LL. Mosaic blood vessels in tumors : frequency of cancer cells in contact with flowing blood. *Proc Natl Acad Sci USA* 2000; 97 : 14608-13.
45. Dvorak HF. Tumors : wound that do not heal. Similarities between tumor stroma generation and wound healing. *N Eng J Med* 1986; 315 : 1650-9.
46. Hemlinger G, Netti PA, Lichtenbeld HC, Melder RJ, Jain PK.. Solid stress inhibits the growth of multicellular tumor spheroids. *Nat Biotechnol* 1997; 15 : 778-83.
47. Brown LF, Guidi AJ, Schnitt SJ, water Lvd, Arispe MLI, Yeo TK, et al. vascular stroma formation in carcinoma in situ, invasive carcinoma, and metastatic carcinoma of the breast. *Clin Cancer Res* 1999; 5 : 1041-56.
48. Achen MG, Stacker SA. The vascular endothelial growth factor family; proteins which guide the development of the vasculature. *Int J Exp Pathol* 1998; 79 : 255-65.
49. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. *J Biol Chem* 1995; 270 : 19761-6.
50. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factorgene transcription by hypoxia-inducible factor 1. *Mol Cell Biol* 1996; 16:4604-13.
51. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. *J Biol Chem* 1995;270:13333-40.
52. Dvorak HF Vascular permeability factor/vascular endothelial growth factor:a critical cytokine in tumor angiogenesis and a potential target for diagnosi and therapy. *J Clin Oncol* 2002;20:4368-80.
53. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. *Kidney Int* 1999;56:794-814

54. Frank S, Hubner G, Breier G, Longaker MT, Greenhalgh DG, Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. *J Biol Chem* 1995; 270:12607-13
55. detchokul,S., Frauman A.G. Recent development in prostate cancer biomarker research : therapeutic implications. 2011. *Br j Clin Pharmacol* / 71:2 / 157 – 174.
56. Serganova I,Humm J, Ling C, Blasberg R. Tumor hypoxia imaging. *Clin Cancer Res* 2006;12 : 5260 – 5264.
57. Carrol VA, Ashcroft M. HIF - 1 α regulation by proline hydroxlation. *Expert reviews in Molecular Medicine*. Vol. 7; Issue 6; 15 April 2005.
58. Folkman, J., Fundamental concepts of the angiogenic process. *Curr Mol Med*, 2003. **3**(7): p. 643-51.
59. Harris AL. Angiogenesis for cancer therapy, *Lancet* 1997, 349 : p.13-5.
60. Robb CS, Brown PR. Catechin in tea : chemistry and analysis. In : Brown PR.Grushka E ed. *Advanced in chromatography*. Marcel Dekker 2001:379-90.
61. Higdon JV, Frei B. Tea catechins and polyphenols : Health effects, metabolism, and antioxidant functions. *Critical reviews in food science and nutrition* 2003.
62. Ohmori R, Iwamoto T, Motomi Tago, akeo T, Unno T, Itakura H et al. Antioxidant activity of various tea againts free radicals and oxydation. *Lipids* 2005;40:8:849-53.
63. Hakim IA, Harris RB, Brown S, Chow HH, wiseman S, Agarwae S et al. Effect of tea consumption on oxidative DNA damage among smokers : A randomized controlled study. *J. Nutr.* 200:133:3303S-09S.
64. Vayalil PK, Elments CA, Katiyar SK. Treatment of green tea polyphenols in hydrophilic cream prevents UVB-induced oxidation of lipids and proteins, depletion of antioxidant enzymes and phosphorylation of MAPK proteins in SKH-1 hairless mouse skin. *Carcinogenesis*. 2003;24:927-36.
65. Nanjo F, Mori M, Goto K, Hara Y. Radical scavenging activity of tea catechins and their related compounds. *Biosci.Biotechnol. Biochem*, 1999;63:1621-23.

66. Anderson RF, Fisher LJ, Hara Y, Harris T, Mak WB, Melton LD et al. Green tea catechins partially protect DNA from OH radical induced strand break and basedamage through fast chemical repair of DNA radicals. *Carcinogenesis*. 2001;22:1189-93.
67. Chow H-H-S, Hakim IA, Vining DR, Crowel JA, Ranger-Moore J, Chew VM et al. Effects of dosing condition on the oral bioavailability of green tea catechins after single dose administration of polyphenon E in healthy individuals. *Clin Cancer Res* 2005;11(12) June 15:4627-33.
68. Valcie S, Burr JA, Timmermann BN, Liebler DC. Antioxidant chemistry of green tea catechins. New oxidation product of epigallocatechin gallate and epigallocatechin from their reactions with peroxy radicals. *Chem Res.Toxicol*. 2000;13:801-10.
69. Holman PC, Tijburg LB, Yang CS. Bioavailability of flavonoids from tea. *Crit Rev Food Sci.Nutr*. 1997; 37:719-38.
70. Chen L, Lee MJ, Li H, Yang CS. Absorption , distribution, elimination of tea polyphenols in rats. *Drug metabolism. Dispos*, 1997; 25:1045-50.
71. Li C, Lee M, Sheng S, Meng X, Prabhu S, Winik B, et al. Structural identification of the metabolites of catechins and their kinetics in human urine and blood after tea ingestion. *Chem. Res Toxicol*. 2000;13:177-84.
72. Nanjo F, Mori M, Goto K, Hara Y. Radical scavenging activity of tea catechins and their related compounds. *Biosci. Biotechnol. Biochem*, 1999;63:1621-23.
73. Van Amelsvoort JM, Van Hof KH, Mahot JN, Mulder TP, Wiersma A, Tijburg LB.. Plasma concentrations of individual tea catechins after a single oral dose in humans. *Xenobiotica*, 2001;31:891-901
74. Suganuma M, Okabe S, Oniyama M, Tada Y, Ito H, Fujiki H. Wide distribution of epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue. *Carcinogenesis* 1998;10:1771-76.

75. Kim S, Lee MJ, Hong J, Li C, Smith TJ, Yang GY et al. Plasma and tissue levels of tea catechins in rats and mice during chronic consumption of green tea polyphenols. *Nutr. Cancer* 2000;37:41-8.
76. Yang F, De Villiers WJS, McClain CJ, Varilek GW. Green tea polyphenols block endotoxin induced tumor necrosis factor-production and lethality in a murine model. *J Nutr* 1998;126:2332-40.
77. Williamson G. Dietary intake and bioavailability of polyphenols. *J Nutr* 2000;130:2073S-85S.
78. Chen CH, Ho ML, Chang JK, Hung SH, Wang GJ. Green tea catechins enhance the expression of osteoprotegerin (OPG) in pluripotent stem cells. *J Orthop Surg Taiwan* 2003;20:178-83.
79. Chieh-Chen H, Jai-You F, Wen-Bin W, Chiang HS, Wei YJ, Hung CF et al. Protective effects of epicatechin 3 gallate on UVA induced damage in HaCaT keratinocytes. *Arch Dermatol Res* 2005;296:473-81.
80. Mantena SK, Meeran SM, Elmtes CA, Katiyar SK. Orally administration green tea polyphenols prevent ultraviolet radiation induced skin cancer in mice through activation of cytotoxic T cells and inhibition of angiogenesis in tumors. *The journal of nutrition* 2005 Dec 135:12:2871
81. Na HK and YJ Surh. Intracellular signaling network as a prime chemopreventive target of epigallocatechin gallate. *Mol Nutr Food Res*,2006,50(2) : p.152-9.
82. Zhu, B.H., Zhan WH, He YL, Cai SR, Wang Z, Zhang CH. (-)-Epigallocatechin-3-gallate inhibits growth of gastric cancer by reducing VEGF production and angiogenesis. *World J Gastroenterol*, 2007. 13(8):p.152-9
83. Adhani VM, Siddiqui IA, Ahmad N, Gupta S, Mukhtar S. Oral consumption of green tea polyphenols inhibits IGF-1induced signaling in an autochthonous mouse model of prostate cancer. *Cancer Research* 64, 2004, p:8715-22.

84. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5 reductase inhibition in human benign prostatic hyperplasia. *Eur Urol* 2000; 37:367-80.
85. Steers WD. 5 α reductase activity in the prostate. *Urology* 2001 : 58 (Suppl 6A) : 17-24.
86. Anderson JB, Roehrborn CG, Schalken JSA, Emberton M. The progression of benign prostatic hyperplasia:examining the evidence and determining the risk. *Eur Urol* 2001; 39:390-9.
87. Kaplan SA. 5 α reductase inhibitors:what role study the play? *Urology* 2001; (Suppl 6 A) : 65-70.
88. Cilotti A, Danza G, Serio M. Clinical application of 5 α reductase inhibitors. *J Endrocrinal Invest* 2001; 24:199-203.
89. Meidan VM, Touitou E. Treatments for androgenic alopecia and alopecia areata:current options and future prospects. *Drugs* 2001; 61:53-69
90. Avodart (Dutasteride) Precribing Information, Glaxo Smith Kline
91. Proscar (Finasteride) Prescribing Information,Merck & Co, Inc
92. Wilde MI, Goa KL. Finasteride. An update of its use in the management of symptomatic benign prostatic hyperplasia. *Drugs* 1999; 57:557-81
93. Mc Connell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5 α reductase, suppresses prostatic dihydrotestosterone in man with benign prostate hyperplasia. *J Clin Endocrinolog Metab.* 1992 Mar, 74 (3) : 505 - 8.
94. Marshall S, Narayan P. Treatment of prostatic bleeding : Supression of angiogenesis by androgen deprivation, *J Urol*, 1993,149 : 1553-4.
95. Hayek OR, Shabsigh A, Kaplan SA, Kiss AJ, Chen M, Burchardt T, et al. Castration induces acute vasoconstriction of blood vessels in the rat prostate concomitant with reduction of prostatic nitric oxide synthase activity, *J Urol*,1999, 162 : 1527-31

96. Haggstrom S, Lissbrant IF, Bergh A, Damber J. Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats, *J Urol*, 1999, 161 : 1620-25
97. Puchner PJ, Miller MI. The effects of finasteride on haematuria associated with benign prostatic hyperplasia : A preliminary report, *J Urol*, 1995, 154 : 1779-82
98. Sieber PR, Rommel FM, Huffnagle HW, Breslin JA, Augusta VE, Harpster LE The treatment of gross hematuria secondary to prostatic bleeding with finasteride, *J Urol*, 1998, 159 : 1232-33
99. World Health Organization. Research guidelines for evaluating the safety and efficacy of herbal medicines. New York; 1993.p. 44
100. Weidner, N., Carroll PR, Flax J, Blumenfeld W, Folkman J Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. *Am J Pathol*, 1993. 143(2): p. 401-9.
101. Mabjesh, N. Willard, Frederickson, Zhong CE, Simons JW. Androgen Stimulate Hypoxia – inducible Factor 1 Activation via Autocrine Loop of Tyrosine Kinase Receptor / Phosphatidylinositol 3' – Kinase / Protein Kinase B in Prostate Cancer Cells. *Clinical Cancer Research*. 2003. Vol. 9 : p.2416.
102. Liao S, Hiipakka RS. Selective Inhibition of Steroid 5 alpha – reductase isoenzymes by tea epicatechin – 3 – gallate and epigallocatechin – 3 – gallate. *Biochem Biophys Res Commun*. 1995 Sep 25; 214 (3): 833 – 8.
103. Pastore A L, Palleschi G, Mariani S, Barrese F, Valentini MA, Cappa M et al. Transurethral Resection of Prostate and The Role of Pharmacological Treatment With Dutasteride in Decreasing Surgical Blood Loss. *J Endourol*. 2013 Jan;27(1):68-70. doi: 10.1089/end.2012.0231. Epub 2012 Oct 3.
104. Hahn RG, Fagerstrom T, Tammela TL, Van Vierssen Trip O, Beisland HO, Duggan A et al. Blood Loss and Postoperative Complications Associated with Transurethral Resection of the Prostate After Pretreatment with Dutasteride. *BJU Int* 2007 Mar; 99(3):587 – 94.

105. Boccon – Gibod L, Valton M, Ibrahim H, Comenducci A. Effect of Dutasteride on Reduction of Intraoperative Bleeding Related to Transurethral Resection of Prostate. *Prog Urol*. 2005 Dec; 15(6): 1085 – 9.
106. Hilpakka RA, Zang HZ, Dai W, Dai Q, Liao S. Structure – activity relationships for inhibition of human 5 alpha – reductases by polyphenols. *Biochem Pharmacol*. 2002. Mar 15;63(6):1165 – 76.
107. Drsata J. Enzyme inhibition in the drug therapy of benign prostate hyperplasia. *Cas Lek Cesk*. 2002 Oct 11;141(20):630 – 5.
108. Ather MH, Faruqui N, Abid F. Optimization of Low pre – operative Hemoglobin reduces transfusion requirement in patients undergoing Transurethral Resection of Prostate. *JPMA* 2003. 53:1 04.
109. Kirollos MM, Campbell N. Factors influencing blood loss in transurethral resection of the prostate (TURP) : auditing TURP. *Br J Urol* 1997;80: III – IS.
110. Miyao H, Kotake Y, Kakoi H, Sekiguchi H, Kawazoe T. TURP Syndrome and Changes in Body Fluid Distribution. *J Saitama Med School* 2001; 28 : 1 – 8.
111. Matsumura A, Kubota T, Taiyoh H, Fujiwara H, Okamoto K, Ichikawa D et al. HGF regulates VEGF expression via the c-Met receptor downstream pathways, PI3K/Akt, MAPK and STAT3, in CT26 murine cells. *International Journal of Oncology* 2013;42: 535 – 542.